市場調查報告書

生物標記的全球市場:成長,趨勢,及預測

Biomarkers Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 911966
出版日期 內容資訊 英文 114 Pages
商品交期: 2-3個工作天內
價格
生物標記的全球市場:成長,趨勢,及預測 Biomarkers Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年09月01日內容資訊: 英文 114 Pages
簡介

本報告提供全球生物標記市場的相關調查,提供市場機會和趨勢,成長及阻礙因素,疾病·類型·機制·各地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 成長要素
  • 阻礙因素
  • 波特的五力分析

第5章 市場區隔

  • 各疾病
    • 癌症
    • 心血管障礙
    • 神經學的障礙
    • 免疫疾病
    • 腎障礙
    • 其他
  • 各類型
    • 預後生物標記
    • 藥效學的生物標記
    • 替代端點標記
  • 各作用機制
    • 遺傳基因生物標記
    • 表觀遺傳生物標記
    • 蛋白質組生物標記
    • 脂質生物標記
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Abbott Laboratories, Inc.
    • Aushon Biosystem
    • Bio-Rad Laboratories
    • Epigenomics AG
    • Epistem Ltd
    • Johnson & Johnson
    • Qiagen N.V
    • Roche Diagnostics
    • Siemens Healthcare GmbH
    • Thermo Fisher Scientific Inc.

第7章 市場機會及今後趨勢

目錄
Product Code: 66765

Market Overview

A biomarker refers to a biological molecule or gene that is used to effectively and accurately evaluate pharmacologic responses, pathogenic procedures, and biological procedures. Also known as a molecular marker or signature molecule, biomarkers are found in blood, other body fluids, and tissue.

The global market for biomarkers is gaining traction from a number of factors, including increasing prevalence and diagnosis of life-threatening diseases like cancer, cardiovascular diseases, neurological disorders, etc., which is in turn raising the awareness and increasing the demand for early diagnosis, reducing cost of clinical trials in various emerging economies, increasing investment in research and development by biotechnology and pharmaceutical companies, and new initiatives regarding biomarker research. On the other hand, the biomarkers market is facing challenges from high capital investments, the low cost-benefit ratio with total investment, and poorly suited regulatory and reimbursement systems. Nevertheless, vastly populated emerging economies in the Asia Pacific such as India and China are expected to open new revenue avenues for the companies operating in the biomarkers market, provided they can prove the clinical validity of the tests.

Scope of the Report

In the report, a detailed analysis of the global biomarkers market is provided. The market is evaluated by collating revenues generated across segments, categorized by biomarker type, disease, Mechanism, and Geography.

Key Market Trends

Cancer Biomarkers dominate the market

Development of advanced genomic analysis technique, the introduction of effective guidelines for biomarkers manufacturing, huge amount of research by Cancer societies and proven effectiveness of transplants are some of the primary growth stimulants for the segment. Although manufacturing and pharmacological issues and regulatory hurdles are hindering the growth of the market, the development of products from research institutes has been propelling the growth of this market. For instance, in January 2018, Researchers from University of Luxembourg have discovered a new biomarker for colorectal cancer which classifies patients into "high" and "low" risk group which may help oncologists to choose the adequate treatment for a particular patient.

North America Dominates the Market in the Forecast Period

North America currently dominates the market for renal biomarkers and is expected to continue its stronghold for a few more years. In the North American region, the United States holds the largest market share. Over the past decade, there has been a significant increase in the number of USFDA-approved drug labels containing information on molecular biomarkers. Almost every pharmaceutical company has been developing molecular biomarker programs, either through partnerships or through other ventures. Molecular biomarkers are expected to be identified and validated in drug development and be used to support the approval of drug products. Such drug approvals are helping the renal biomarkers market grow in the United States.

Competitive Landscape

Majority of the biomarker assays and tests are being manufactured by the global key players. Market leaders with more funds for research and better distribution system have established their position in the market. Moreover, due rise of awareness and hence increasing market, Asia-pacific is witnessing an emergence of some small players.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Life-Threatening Diseases
    • 4.2.2 Increasing Demand for Early Diagnosis of Diseases
    • 4.2.3 Research Advancements in finding new Biomarkers
  • 4.3 Market Restraints
    • 4.3.1 Issues Related to Regulatory and Reimbursement Systems
    • 4.3.2 High Cost of Biomarkers
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Disease
    • 5.1.1 Cancer
    • 5.1.2 Cardiovascular Disorders
    • 5.1.3 Neurological Disorders
    • 5.1.4 Immunological Disorders
    • 5.1.5 Renal Disorders
    • 5.1.6 Others
  • 5.2 By Type
    • 5.2.1 Prognostic Biomarkers
    • 5.2.2 Prognostic Biomarkers
    • 5.2.3 Pharmacodynamic Biomarkers
    • 5.2.4 Surrogate End Point Markers
  • 5.3 By Mechanism
    • 5.3.1 Genetic biomarkers
    • 5.3.2 Epigenetic biomarkers
    • 5.3.3 Proteomic biomarkers
    • 5.3.4 Lipidomic biomarkers
    • 5.3.5 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 US
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 UK
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories, Inc.
    • 6.1.2 Aushon Biosystem
    • 6.1.3 Bio-Rad Laboratories
    • 6.1.4 Epigenomics AG
    • 6.1.5 Epistem Ltd
    • 6.1.6 Johnson & Johnson
    • 6.1.7 Qiagen N.V
    • 6.1.8 Roche Diagnostics
    • 6.1.9 Siemens Healthcare GmbH
    • 6.1.10 Thermo Fisher Scientific Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS